JCV Vaccine
John Cunningham virus reactivation leading to Progressive Multifocal Leukoencephalopathy (PML)
Pre-clinicalActive
Key Facts
Indication
John Cunningham virus reactivation leading to Progressive Multifocal Leukoencephalopathy (PML)
Phase
Pre-clinical
Status
Active
Company
About Belyntic
Belyntic is an early-stage, preclinical biotech company pioneering a novel vaccine platform called T-Fender, designed to induce strong and lasting cellular (T cell) immunity. The company is initially targeting latent viral infections like Cytomegalovirus (CMV) and John Cunningham virus (JCV) in immunocompromised patients, a population with high unmet medical need. Led by a small, dual-managing director team, Belyntic is actively seeking partnerships to advance its portfolio and drive innovation in the field of T cell-inducing vaccines.
View full company profile